Targeting CD22 reprograms B-cells and reverses autoimmune diabetes

Area of Science:

• Immunology
• Endocrinology
• Translational Medicine

Background:

• Autoimmune diabetes, such as type 1 diabetes, is driven by immune system dysfunction.
• Current treatments for autoimmune diabetes are limited and often focus on managing symptoms rather than addressing the underlying cause.

Purpose of the Study:

• To investigate a B-cell-depleting strategy targeting the CD22 receptor to reverse autoimmune diabetes in non-obese diabetic (NOD) mice.
• To assess the potential of reprogramming B-cells as a therapeutic approach for autoimmune diabetes.

Main Methods:

• Utilized an anti-CD22/cal monoclonal antibody (mAb) to deplete and reprogram B-cells in naïve NOD mice.
• Administered therapy to pre-diabetic and newly hyperglycemic mice to evaluate efficacy and timing of intervention.
• Analyzed changes in regulatory T-cells, immune responses to islet peptides, and gene expression in reemerging B-cells.

Main Results:

• Anti-CD22/cal mAb therapy led to early and sustained B-cell depletion, delaying disease onset in pre-diabetic mice.
• In newly hyperglycemic mice, 100% of B-cell-depleted mice achieved normoglycemia within 2 days, with 70% maintaining long-term normoglycemia.
• Therapy increased regulatory T-cells, diminished immune responses to islet peptides, and reprogrammed reemerging B-cells to prevent diabetes in adoptive transfer models.

Conclusions:

• Targeting CD22 effectively depletes and reprograms B-cells, leading to the reversal of autoimmune diabetes in a preclinical model.
• This B-cell-centric approach offers a novel therapeutic blueprint for potentially curing autoimmune diabetes.